Excipients in Pharmaceuticals
Report Highlights
The global excipients market should reach nearly $6.9 billion by 2020 from approximately $6.3 billion in 2015, at a compound annual growth rate (CAGR) of 1.9% from 2015 to 2020.
Report Includes
- An overview of the global market for excipients in pharmaceuticals, including examinations of the effects of a crisis in the global supply chain, the demands of quality by design (QbD), and concerns about drug safety.
- Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020.
- Discussion of positive trends in the industry, including the development of creative ideas in response to the need for new excipients and new levels of cooperation between major players.
- Coverage of the most important issues surrounding excipients: technological, regulatory, economic, and political.
- Evaluations of excipient technology by chemical compounds, functional uses, delivery systems and finished products.
- Profiles of suppliers and others relevant to the industry.
SCOPE OF THE STUDY
This study encompasses excipients in pharmaceutical and biopharmaceutical markets. BCC analyzes each market by type and functional use, regulation, market projections, and market shares. The latest technological trends and developments are discussed. The last section provides company profiles of many of the companies relevant to the industry.
Organic is segmented into carbohydrates, oleochemicals, petrochemicals, proteins and others. Each is then further divided.
Inorganics are segmented into calcium salts, halites, metal oxides, silicates and others. Each is then further segmented.
Excluded from the study are ingredients for cosmetics, personal care products, food, quasi-medical products, unorthodox/alternative therapies, home remedies, underground and/or illegal drugs and veterinary drugs.
Analyst Credentials
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
Report Highlights
The global excipient market reached nearly $5.9 billion in 2012. This market is expected to grow to $6.3 billion in 2013 and then to $8.8 billion in 2018, a compound annual growth rate (CAGR) of 6.9% over the five-year period from 2013 to 2018.
Report Includes
- An overview of the global market for excipients in pharmaceuticals, including examinations of the effects of a crisis in the global supply chain, the demands of quality by design (QbD), and concerns about drug safety
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
- Discussion of positive trends in the industry, including the development of creative ideas in response to the need for new excipients and new levels of cooperation between major players
- Coverage of the most important issues surrounding excipients: technological, regulatory, economic, and political
- Evaluations of excipient technology by chemical compounds, functional uses, delivery systems and finished products
- Comprehensive company profiles of suppliers and others relevant to the industry.
Report Highlights
The global excipients market was at $4.6 billion in 2010 and it is expected to reach at $4.9 billion in 2011. It is further anticipated to increase to $6.7 billion by 2016 at a compound annual growth rate (CAGR) of 6.5%.
Report Highlights
- Overall sales in the global excipients market were worth $4.1 billion in 2008, and increased to an estimated $4.3 billion in 2009. By 2014, it is projected to increase to $5.9 billion, for a 5-year compound annual growth rate (CAGR) of 6.3%.
- The largest segment of the market, organic chemicals, was valued at $3.8 billion in 2008; this is expected to increase to $4 billion in 2009, and is projected to reach $5.5 billion in 2014, for a 5-year CAGR of 6.4%.
- Sales in the USP (U.S. Pharmacopeia-grade) Water segment amounted to $79 million in 2008, increased to an estimated $84 million in 2009, and is projected to increase to $104 million in 2014, for a 5-year CAGR of 4.4%.
Report Highlights
-
The chemical compounds used to make excipients are valued at $4.3 billion market value for 2011, up from $3.5 billion in 2006. The dominance of USP water, particularly water for injection, skews the market volume and sets the pace for the anticipated 5.1% average annual market volume growth rate over the next five years.
-
Formulators will continue to use excipients to give their final drug products the necessary or desired functional use or properties. Vehicles, with an estimated 2011 market volume of 9.6 billion pounds, lead due to the large amount of USP water consumed.
-
Fillers follow with an estimated 849 million pounds of excipient chemical compounds being used in that functional category in five years. In terms of market value, the situation is reversed. Fillers come out on top, with an estimated 2011 market value of $1.2 billion, and vehicles drop to third place with $781 million, just below emollients at $816 million.
Report Highlights
-
In 2001, the global market for pharmaceutical (drug) inert ingredients was an estimated 7.25 billion pounds, of which water, accounted for about 77% of the total.
-
Overall growth of all drug inert ingredients is the order of 5% per year.
-
Injectables, essentially all Rx, constitute the single largest dosage form of excipients used in 2001 with almost 1.9 billion Kgs.
-
Nonaqueous biological use will grow to 563 million Kgs by 2007, an average annual growth rate (AAGR) of 4.5%.
